Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma

NCT00514475 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: 90Y-ibritumomab tiuxetan (Zevalin)

Sponsor

Oslo University Hospital